Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Sotio Biotech Inc.
Royal Marsden NHS Foundation Trust
Novartis
Incyte Corporation
Merck Sharp & Dohme LLC
Turnstone Biologics, Corp.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc